Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-19-015154
Filing Date
2019-08-09
Accepted
2019-08-09 16:31:43
Documents
92
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0619_elitepharma.htm 10-Q 959245
2 CERTIFICATION f10q0619ex31-1_elite.htm EX-31.1 15721
3 CERTIFICATION f10q0619ex31-2_elite.htm EX-31.2 15765
4 CERTIFICATION f10q0619ex32-1_elite.htm EX-32.1 5578
5 CERTIFICATION f10q0619ex32-2_elite.htm EX-32.2 5598
  Complete submission text file 0001213900-19-015154.txt   5250666

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE eltp-20190630.xml EX-101.INS 869427
7 XBRL SCHEMA FILE eltp-20190630.xsd EX-101.SCH 76176
8 XBRL CALCULATION FILE eltp-20190630_cal.xml EX-101.CAL 61333
9 XBRL DEFINITION FILE eltp-20190630_def.xml EX-101.DEF 250173
10 XBRL LABEL FILE eltp-20190630_lab.xml EX-101.LAB 459939
11 XBRL PRESENTATION FILE eltp-20190630_pre.xml EX-101.PRE 374427
Mailing Address 165 LUDLOW AVENUE NORTHVALE NJ 07647
Business Address 165 LUDLOW AVENUE NORTHVALE NJ 07647 2017502646
ELITE PHARMACEUTICALS INC /NV/ (Filer) CIK: 0001053369 (see all company filings)

EIN.: 223542636 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 001-15697 | Film No.: 191013362
SIC: 2834 Pharmaceutical Preparations